Literature DB >> 26642940

Heat shock protein 90 inhibitors induce functional inhibition of human natural killer cells in a dose-dependent manner.

Ting Huyan1, Qi Li1, Dan-Dan Dong1, Hui Yang1, Jian Zhang1, Qing-Sheng Huang1, Da-Chuan Yin1, Peng Shang1.   

Abstract

Heat shock protein 90 (Hsp90) is a ubiquitously expressed ATP-dependent molecular chaperone across all species that helps to the correct the folding of many proteins related to important signaling pathways. Tumor cells expressing Hsp90 have more ATP-binding affinity than normal cells. Many correlative inhibitors have been developed to promising anti-tumor strategies and have been evaluated in clinical trials. However, the effect of Hsp90 inhibitors on immunocytes cannot be ignored. Natural killer (NK) cells are key components of the innate immune system that play a pivotal role in tumor surveillance. The present study has investigated the potential effect of four Hsp90 inhibitors (NVP-AUY922, BIIB021, 17-DMAG, and SNX-2112) on human primary NK cells. The viability, cytotoxicity, apoptosis, phenotype, and cytokine secretion of NK cells after inhibitor treatment were assessed. The results of this study demonstrated that the inhibitors had negative effects on NK cell activity in a dose-dependent manner. The four inhibitors significantly reduced the cytotoxicity of the NK cells by decreasing viability, inducing apoptosis and down-regulating the expression of cytokines and functional receptors. These findings suggest that more attention should be given to the effect of Hsp90 inhibitors on NK cell function during clinical trials and also represent a potential immunosuppressant strategy.

Entities:  

Keywords:  Apoptosis; Hsp90 inhibitors; cytotoxicity; human natural killer cells; immunotherapy

Mesh:

Substances:

Year:  2015        PMID: 26642940     DOI: 10.3109/08923973.2015.1119159

Source DB:  PubMed          Journal:  Immunopharmacol Immunotoxicol        ISSN: 0892-3973            Impact factor:   2.730


  3 in total

1.  The HSP-RTK-Akt axis mediates acquired resistance to Ganetespib in HER2-positive breast cancer.

Authors:  Christopher E Eyermann; John D Haley; Evguenia M Alexandrova
Journal:  Cell Death Dis       Date:  2021-01-26       Impact factor: 8.469

Review 2.  The HSP Immune Network in Cancer.

Authors:  Zarema Albakova; Yana Mangasarova
Journal:  Front Immunol       Date:  2021-11-30       Impact factor: 7.561

Review 3.  Immunogenic Effect of Hyperthermia on Enhancing Radiotherapeutic Efficacy.

Authors:  Sungmin Lee; Beomseok Son; Gaeul Park; Hyunwoo Kim; Hyunkoo Kang; Jaewan Jeon; HyeSook Youn; BuHyun Youn
Journal:  Int J Mol Sci       Date:  2018-09-17       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.